search
Back to results

THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

Primary Purpose

Peripheral Arterial Disease, Claudication, Claudication, Intermittent

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
SPM Emulsion, Dose-modality
SPM Softgel, Dose-Modality
Placebo Softgel
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Peripheral Arterial Disease focused on measuring peripheral arterial disease, claudication, PAD, Vascular Disease, Vascular Occlusion, Vacular Calcification, intermittent claudication, Osteoarthritis

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Healthy Volunteers:

-Age 20-80

PAD Patients:

  • Mild claudication to rest pain (Rutherford 1-4)
  • Resting or exercise ABI < 0.9 or TBI < 0.6
  • Age 40 and more

OA Patients:

-Lower extremity (hip or knee) OA

Exclusion Criteria:

PAD, OA Patients and Healthy Volunteers:

  • Plan to undergo surgical procedure or PVI for treatment of PAD within one month
  • Evidence of active infection
  • Hypersensitivity or allergy to fish or seafood
  • Already on n-3 PUFA or equivalent
  • Chronic liver disease, end-stage renal disease (CKD 5), or chronic inflammatory disorders
  • Poorly controlled diabetes (HbA1C > 8%)
  • BMI < 20 or >35
  • Recent other major surgery or illness within 30 days
  • Use of immunosuppressive medications or steroids
  • History of organ transplantation
  • Pregnancy, or plans to become pregnant, or lactating

Healthy Volunteers:

  • hsCRP > 2mg/L
  • Regular aspirin use
  • Regular non-steroidal anti-inflammatory drug use

Sites / Locations

  • University of California San Francisco

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Placebo Comparator

Arm Label

Phase 1a (OMEGA-SPM-DOSE)

SPM - Phase 1b (OMEGA-SPM-DOSE)

Placebo - Phase 1b (OMEGA-SPM-PLACEBO)

Arm Description

PAD patients and healthy volunteers in study for SPM Emulsion, dose-modality.

PAD and Osteoarthritis (OA) patients using softgel, dose-modality.

PAD and Osteoarthritis (OA) patients using softgel, dose-modality.

Outcomes

Primary Outcome Measures

Optimal Phase 1b Dose
The smallest dose administered in Phase 1a participants which results in an increase in Resolution Index at least 3 times that of baseline, or the subsequent larger dose resulting in a Resolution Index greater than 2 times that of the preceding does with no increase in side effects at the larger dose.
Change in the Resolution Index
Integrated metabolo-lipidomics assessment of SPM pathways: Average concentration of 15-HEPE, 18-HEPE, 4-HDHA, and 17-HDHA in plasma.

Secondary Outcome Measures

Full Information

First Posted
March 21, 2016
Last Updated
May 4, 2021
Sponsor
University of California, San Francisco
search

1. Study Identification

Unique Protocol Identification Number
NCT02719665
Brief Title
THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease
Official Title
THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
March 2016 (Actual)
Primary Completion Date
December 15, 2020 (Actual)
Study Completion Date
December 15, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to understand the effects of fish oil supplement (containing parts of omega-3 fatty acids) on inflammation. The investigators are aiming to identify which dose of the fish oil supplement is the most effective. The name of the fish oil supplement is "SPM Emulsion."
Detailed Description
The OMEGA-SPM-DOSE trial and the OMEGA-SPM-PAD trial are two parts of a pilot study which aims to investigate the effect of a novel formulation of a nutritional supplement containing highly concentrated n-3 PUFA metabolites (SPM Emulsion) on the metabolo-lipidomic profile of healthy volunteers and patients with Peripheral Arterial Disease(PAD). Ten healthy volunteers and ten patients with PAD will participate in Part 1a, the "OMEGA-SPM-DOSE Study". A follow-up, placebo controlled, prospective study on the best dosing modality determined in Phase 1a will then take place in a PAD and OA population (n=12), Phase 1b - the "OMEGA-SPM-PAD Study". Specific measurements will include targeted metabolo-lipidomic profiling, established markers of inflammation, and functional monocyte and macrophage assays. The proposed studies have the potential to provide important new insights on the role of nutritional interventions in PAD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease, Claudication, Claudication, Intermittent, Vascular Occlusion, Vascular Calcification, Vascular Diseases, Osteoarthritis
Keywords
peripheral arterial disease, claudication, PAD, Vascular Disease, Vascular Occlusion, Vacular Calcification, intermittent claudication, Osteoarthritis

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Phase 1a (OMEGA-SPM-DOSE)
Arm Type
Experimental
Arm Description
PAD patients and healthy volunteers in study for SPM Emulsion, dose-modality.
Arm Title
SPM - Phase 1b (OMEGA-SPM-DOSE)
Arm Type
Active Comparator
Arm Description
PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
Arm Title
Placebo - Phase 1b (OMEGA-SPM-PLACEBO)
Arm Type
Placebo Comparator
Arm Description
PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
Intervention Type
Dietary Supplement
Intervention Name(s)
SPM Emulsion, Dose-modality
Other Intervention Name(s)
Omega SPM, Specialized Pro-resolving Lipid Mediator Emulsion
Intervention Description
Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule: Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml
Intervention Type
Dietary Supplement
Intervention Name(s)
SPM Softgel, Dose-Modality
Other Intervention Name(s)
Omega SPM Bridging
Intervention Description
Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo Softgel
Other Intervention Name(s)
Omega SPM Bridging
Intervention Description
Days 43-47: 4 Placebo softgel; Day 48-64 Washout
Primary Outcome Measure Information:
Title
Optimal Phase 1b Dose
Description
The smallest dose administered in Phase 1a participants which results in an increase in Resolution Index at least 3 times that of baseline, or the subsequent larger dose resulting in a Resolution Index greater than 2 times that of the preceding does with no increase in side effects at the larger dose.
Time Frame
Baseline, Day 33
Title
Change in the Resolution Index
Description
Integrated metabolo-lipidomics assessment of SPM pathways: Average concentration of 15-HEPE, 18-HEPE, 4-HDHA, and 17-HDHA in plasma.
Time Frame
Baseline, Day 5

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy Volunteers: -Age 20-80 PAD Patients: Mild claudication to rest pain (Rutherford 1-4) Resting or exercise ABI < 0.9 or TBI < 0.6 Age 40 and more OA Patients: -Lower extremity (hip or knee) OA Exclusion Criteria: PAD, OA Patients and Healthy Volunteers: Plan to undergo surgical procedure or PVI for treatment of PAD within one month Evidence of active infection Hypersensitivity or allergy to fish or seafood Already on n-3 PUFA or equivalent Chronic liver disease, end-stage renal disease (CKD 5), or chronic inflammatory disorders Poorly controlled diabetes (HbA1C > 8%) BMI < 20 or >35 Recent other major surgery or illness within 30 days Use of immunosuppressive medications or steroids History of organ transplantation Pregnancy, or plans to become pregnant, or lactating Healthy Volunteers: hsCRP > 2mg/L Regular aspirin use Regular non-steroidal anti-inflammatory drug use
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Conte, M.D.
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
26296857
Citation
Grenon SM, Owens CD, Nosova EV, Hughes-Fulford M, Alley HF, Chong K, Perez S, Yen PK, Boscardin J, Hellmann J, Spite M, Conte MS. Short-Term, High-Dose Fish Oil Supplementation Increases the Production of Omega-3 Fatty Acid-Derived Mediators in Patients With Peripheral Artery Disease (the OMEGA-PAD I Trial). J Am Heart Assoc. 2015 Aug 21;4(8):e002034. doi: 10.1161/JAHA.115.002034.
Results Reference
background
PubMed Identifier
24052491
Citation
Grenon SM, Owens CD, Alley H, Chong K, Yen PK, Harris W, Hughes-Fulford M, Conte MS. n-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: the OMEGA-PAD trial. Vasc Med. 2013 Oct;18(5):263-74. doi: 10.1177/1358863X13503695. Epub 2013 Sep 19.
Results Reference
background
PubMed Identifier
25777995
Citation
Akagi D, Chen M, Toy R, Chatterjee A, Conte MS. Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J. 2015 Jun;29(6):2504-13. doi: 10.1096/fj.14-265363. Epub 2015 Mar 16.
Results Reference
background
PubMed Identifier
25409514
Citation
Chatterjee A, Sharma A, Chen M, Toy R, Mottola G, Conte MS. The pro-resolving lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells. PLoS One. 2014 Nov 19;9(11):e113480. doi: 10.1371/journal.pone.0113480. eCollection 2014.
Results Reference
background
PubMed Identifier
23407709
Citation
Miyahara T, Runge S, Chatterjee A, Chen M, Mottola G, Fitzgerald JM, Serhan CN, Conte MS. D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J. 2013 Jun;27(6):2220-32. doi: 10.1096/fj.12-225615. Epub 2013 Feb 13.
Results Reference
background
PubMed Identifier
16847262
Citation
Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A, Serhan CN, Kang JX. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11276-81. doi: 10.1073/pnas.0601280103. Epub 2006 Jul 17.
Results Reference
background
PubMed Identifier
24692596
Citation
Recchiuti A, Codagnone M, Pierdomenico AM, Rossi C, Mari VC, Cianci E, Simiele F, Gatta V, Romano M. Immunoresolving actions of oral resolvin D1 include selective regulation of the transcription machinery in resolution-phase mouse macrophages. FASEB J. 2014 Jul;28(7):3090-102. doi: 10.1096/fj.13-248393. Epub 2014 Apr 1.
Results Reference
background
PubMed Identifier
25616438
Citation
Wang X, Hjorth E, Vedin I, Eriksdotter M, Freund-Levi Y, Wahlund LO, Cederholm T, Palmblad J, Schultzberg M. Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. J Lipid Res. 2015 Mar;56(3):674-681. doi: 10.1194/jlr.P055418. Epub 2015 Jan 23.
Results Reference
background
PubMed Identifier
22538616
Citation
Chiang N, Fredman G, Backhed F, Oh SF, Vickery T, Schmidt BA, Serhan CN. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature. 2012 Apr 25;484(7395):524-8. doi: 10.1038/nature11042.
Results Reference
background
PubMed Identifier
23186989
Citation
Mizwicki MT, Liu G, Fiala M, Magpantay L, Sayre J, Siani A, Mahanian M, Weitzman R, Hayden EY, Rosenthal MJ, Nemere I, Ringman J, Teplow DB. 1alpha,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-beta phagocytosis and inflammation in Alzheimer's disease patients. J Alzheimers Dis. 2013;34(1):155-70. doi: 10.3233/JAD-121735.
Results Reference
background
PubMed Identifier
21206090
Citation
Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest. 2011 Feb;121(2):569-81. doi: 10.1172/JCI42545. Epub 2011 Jan 4.
Results Reference
background
PubMed Identifier
19103881
Citation
Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med. 2009 Jan 16;206(1):15-23. doi: 10.1084/jem.20081880. Epub 2008 Dec 22.
Results Reference
background
PubMed Identifier
17090225
Citation
Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101-37. doi: 10.1146/annurev.immunol.25.022106.141647.
Results Reference
background
PubMed Identifier
24899309
Citation
Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014 Jun 5;510(7503):92-101. doi: 10.1038/nature13479.
Results Reference
background
PubMed Identifier
9887164
Citation
Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115-26. doi: 10.1056/NEJM199901143400207. No abstract available.
Results Reference
background
PubMed Identifier
16087797
Citation
Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation. 2005 Aug 16;112(7):976-83. doi: 10.1161/CIRCULATIONAHA.104.513085. Epub 2005 Aug 8.
Results Reference
background
PubMed Identifier
16275181
Citation
Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol. 2005 Nov 15;96(10):1374-8. doi: 10.1016/j.amjcard.2005.07.041. Epub 2005 Sep 27.
Results Reference
background
PubMed Identifier
11368701
Citation
Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001 May 16;285(19):2481-5. doi: 10.1001/jama.285.19.2481.
Results Reference
background
PubMed Identifier
9490235
Citation
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998 Feb 10;97(5):425-8. doi: 10.1161/01.cir.97.5.425.
Results Reference
background
PubMed Identifier
20471776
Citation
Criqui MH, Ho LA, Denenberg JO, Ridker PM, Wassel CL, McDermott MM. Biomarkers in peripheral arterial disease patients and near- and longer-term mortality. J Vasc Surg. 2010 Jul;52(1):85-90. doi: 10.1016/j.jvs.2010.02.004. Epub 2010 May 14.
Results Reference
background
PubMed Identifier
18410327
Citation
Carriere I, Dupuy AM, Lacroux A, Cristol JP, Delcourt C; Pathologies Oculaires Liees a l'Age Study Group. Biomarkers of inflammation and malnutrition associated with early death in healthy elderly people. J Am Geriatr Soc. 2008 May;56(5):840-6. doi: 10.1111/j.1532-5415.2008.01677.x. Epub 2008 Apr 9.
Results Reference
background
PubMed Identifier
18195333
Citation
Vidula H, Tian L, Liu K, Criqui MH, Ferrucci L, Pearce WH, Greenland P, Green D, Tan J, Garside DB, Guralnik J, Ridker PM, Rifai N, McDermott MM. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med. 2008 Jan 15;148(2):85-93. doi: 10.7326/0003-4819-148-2-200801150-00003.
Results Reference
background
PubMed Identifier
17123769
Citation
Owens CD, Ridker PM, Belkin M, Hamdan AD, Pomposelli F, Logerfo F, Creager MA, Conte MS. Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg. 2007 Jan;45(1):2-9; discussion 9. doi: 10.1016/j.jvs.2006.08.048. Epub 2006 Nov 21.
Results Reference
background
PubMed Identifier
19738135
Citation
Conen D, Rexrode KM, Creager MA, Ridker PM, Pradhan AD. Metabolic syndrome, inflammation, and risk of symptomatic peripheral artery disease in women: a prospective study. Circulation. 2009 Sep 22;120(12):1041-7. doi: 10.1161/CIRCULATIONAHA.109.863092. Epub 2009 Sep 8.
Results Reference
background
PubMed Identifier
21571779
Citation
Havelka GE, Kibbe MR. The vascular adventitia: its role in the arterial injury response. Vasc Endovascular Surg. 2011 Jul;45(5):381-90. doi: 10.1177/1538574411407698. Epub 2011 May 13.
Results Reference
background
PubMed Identifier
22017929
Citation
Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011 Oct;4(10):1057-66. doi: 10.1016/j.jcin.2011.05.025.
Results Reference
background
PubMed Identifier
12354979
Citation
Schillinger M, Exner M, Mlekusch W, Rumpold H, Ahmadi R, Sabeti S, Haumer M, Wagner O, Minar E. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. Radiology. 2002 Oct;225(1):21-6. doi: 10.1148/radiol.2251011809.
Results Reference
background
PubMed Identifier
12891123
Citation
Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato A, Schiano V, Scopacasa F. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg. 2003 Aug;38(2):374-9. doi: 10.1016/s0741-5214(03)00124-1.
Results Reference
background
PubMed Identifier
19626421
Citation
Busti C, Falcinelli E, Momi S, Gresele P. Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med. 2010 Feb;5(1):13-25. doi: 10.1007/s11739-009-0283-y. Epub 2009 Jul 21. Erratum In: Intern Emerg Med. 2010 Feb;5(1):89.
Results Reference
background
PubMed Identifier
19679424
Citation
Owens CD, Wake N, Conte MS, Gerhard-Herman M, Beckman JA. In vivo human lower extremity saphenous vein bypass grafts manifest flow mediated vasodilation. J Vasc Surg. 2009 Nov;50(5):1063-70. doi: 10.1016/j.jvs.2009.06.022. Epub 2009 Aug 12.
Results Reference
background
PubMed Identifier
23830313
Citation
Grenon SM, Conte MS, Nosova E, Alley H, Chong K, Harris WS, Vittinghoff E, Owens CD. Association between n-3 polyunsaturated fatty acid content of red blood cells and inflammatory biomarkers in patients with peripheral artery disease. J Vasc Surg. 2013 Nov;58(5):1283-90. doi: 10.1016/j.jvs.2013.05.024. Epub 2013 Jul 2.
Results Reference
background
PubMed Identifier
20709806
Citation
Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AH, Pande R, Creager MA, Serhan CN, Conte MS. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol. 2010 Oct;177(4):2116-23. doi: 10.2353/ajpath.2010.091082. Epub 2010 Aug 13.
Results Reference
background
PubMed Identifier
19481407
Citation
Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009 Jul;50(1):54-60. doi: 10.1016/j.jvs.2009.01.035. Epub 2009 May 28.
Results Reference
background
PubMed Identifier
20940249
Citation
Mahoney EM, Wang K, Keo HH, Duval S, Smolderen KG, Cohen DJ, Steg G, Bhatt DL, Hirsch AT; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes. 2010 Nov;3(6):642-51. doi: 10.1161/CIRCOUTCOMES.109.930735. Epub 2010 Oct 12.
Results Reference
background
PubMed Identifier
21880457
Citation
Sachs T, Pomposelli F, Hamdan A, Wyers M, Schermerhorn M. Trends in the national outcomes and costs for claudication and limb threatening ischemia: angioplasty vs bypass graft. J Vasc Surg. 2011 Oct;54(4):1021-1031.e1. doi: 10.1016/j.jvs.2011.03.281. Epub 2011 Aug 31.
Results Reference
background
PubMed Identifier
21690489
Citation
Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011 Jul 5;124(1):17-23. doi: 10.1161/CIRCULATIONAHA.110.003954. Epub 2011 Jun 20.
Results Reference
background
PubMed Identifier
32696697
Citation
Schaller MS, Chen M, Colas RA, Sorrentino TA, Lazar AA, Grenon SM, Dalli J, Conte MS. Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease. J Am Heart Assoc. 2020 Aug 4;9(15):e016113. doi: 10.1161/JAHA.120.016113. Epub 2020 Jul 22.
Results Reference
derived

Learn more about this trial

THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

We'll reach out to this number within 24 hrs